医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alvogen Launches the First Generic Exelon® Patch in the United States

2015年09月04日 PM09:57
このエントリーをはてなブックマークに追加


 

PINE BROOK, N.J.

Today, Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal system) in the United States. The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the 13.3 mg/24 hours strength, making it eligible for 180 days of marketing exclusivity. Novartis’s Exelon® patch, delivered sales of approximately $400 million USD in the United States during 2014, according to IMS data.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150904005336/en/

Robert Wessman, Chairman and CEO of Alvogen (Photo: Business Wire)

Robert Wessman, Chairman and CEO of Alvogen (Photo: Business Wire)

Robert Wessman, Chairman and CEO of Alvogen, commented: “This exclusive launch is another significant step in Alvogen’s journey. We have demonstrated our ability to move with speed to develop and market high quality generic medicines to our customers and the patients they treat. We are delighted to be able to bring a more affordable alternative to the market.

We have developed over 60 pipeline ANDA’s for the U.S. market, of which 28 have first-to-file or first-to-market potential. This is a clear indication of our progress and our ambition to become one of the leading players in the global pharmaceuticals market.”

Read full release and prescribing information for Rivastigmine Transdermal System on alvogen.com

About Alvogen

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.

The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and China.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150904005336/en/

CONTACT

Alvogen
Halldor Kristmannsson, Global Corporate Marketing &
Communications
(+354) 522 2900, halldor.kristmannsson@alvogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc